Back to top
more

Harpoon Therapy Inc. (HARP)

(Delayed Data from NSDQ)

$10.59 USD

10.59
19,408

-0.41 (-3.73%)

Updated May 3, 2019 04:13 PM ET

After-Market: $10.33 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New Strong Buy Stocks for January 27th

by Zacks Equity Research

GWRS, EVBG, SPLK, RELL and HARP have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2023.

Why Fast-paced Mover Harpoon Therapeutics, Inc. (HARP) Is a Great Choice for Value Investors

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harpoon Therapeutics, Inc. (HARP) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?

by Zacks Equity Research

Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.

Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 41.67% and 73.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurinia (AUPH) delivered earnings and revenue surprises of 66.67% and 46.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 3.64% and 9.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in ProPhase Labs, Inc. (PRPH): Can Its 8% Jump Turn into More Strength?

by Zacks Equity Research

ProPhase Labs, Inc. (PRPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aziyo Biologics, Inc. (AZYO) Moves 7.8% Higher: Will This Strength Last?

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -43.48% and 38.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Invacare (IVC) Q4 Earnings Top Estimates

by Zacks Equity Research

Invacare (IVC) delivered earnings and revenue surprises of 300% and 6.20%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 274% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 274.4% in Harpoon Therapeutics, Inc. (HARP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 1.92% and -29.75%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harpoon Therapeutics, Inc. (HARP) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -15.56% and -11.61%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Harpoon Therapeutics, Inc. (HARP) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Harpoon Therapeutics (HARP) Stock?

by Zacks Equity Research

Investors need to pay close attention to Harpoon Therapeutics (HARP) stock based on the movements in the options market lately.

Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 13.95% and 32.50%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harpoon Therapeutics, Inc. (HARP) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 22.41% and 52.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Harpoon Therapeutics, Inc. (HARP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Harpoon Therapeutics, Inc. (HARP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harpoon's (HARP) Multiple Myeloma Candidate Gets Orphan Drug Tag

by Zacks Equity Research

Harpoon (HARP) gets Orphan Drug designation by the FDA for HPN217 for the treatment of multiple myeloma.

Harpoon (HARP) in Focus: Stock Moves 5.6% Higher

by Zacks Equity Research

Harpoon (HARP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.